|
Hepatitis
|
0.100 |
Biomarker
|
group |
BEFREE |
Plasma alanine aminotransferase (ALT) content was determined and liver inflammation and fibrosis were evaluated.
|
31035991 |
2019 |
|
Hepatitis
|
0.100 |
Biomarker
|
group |
BEFREE |
Results showed that 48 weeks of entecavir treatment caused HBV DNA loss, alanine aminotransferase normalization, and an amelioration of hypergammaglobulinemia in cirrhotic patients; however, telbivudine treatment, though possessing similar efficacies on HBV suppression and an improvement in liver inflammation to entecavir treatment, did not mitigate IgG-related hypergammaglobulinemia.
|
31770396 |
2019 |
|
Hepatitis
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The primary end points were the incidence rates of HBV reactivation (appearance of HBV DNA) and HBV reactivation-related hepatitis (defined as a greater than 3-fold increase in serum alanine aminotransferase levels exceeding 100 IU/L).
|
30581161 |
2019 |
|
Hepatitis
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim of this study was to investigate the utility of noninvasive fibrosis markers including hyaluronic acid (HA), collagen type IV (CIV), N-terminal propeptide of type III procollagen (PIIINP), and laminin (LN) in identifying significant liver inflammation in patients with CHB, especially in patients with normal or near-normal ALT.
|
30537157 |
2019 |
|
Hepatitis
|
0.100 |
Biomarker
|
group |
BEFREE |
A total of 114 CHB patients with spontaneous SAE [alanine aminotransferase (ALT) ≥ 400 U/L] and hepatic decompensation were analyzed along with 114 patients with moderate liver inflammation (ALT: 80-400 U/L without hepatic decompensation) who were matched with the SAE patients in regard to age, sex, HBeAg, and cirrhosis.
|
30835025 |
2019 |
|
Hepatitis
|
0.100 |
AlteredExpression
|
group |
BEFREE |
At reactivation, the median HBV DNA level was 3.89 × 10<sup>4</sup> IU/mL (range, 1.80 × 10<sup>3</sup>-6.00 × 10<sup>7</sup> IU/mL); five had HBV-related hepatitis and one exhibited increasing HBV DNA level without alanine transaminase elevation.No HBV-related fatal events occurred.
|
31753012 |
2019 |
|
Hepatitis
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The butanol extract was observed to significantly reduce the levels of alanine aminotransferase, aspartate transaminase, and lactate dehydrogenase in the sera of mice with concanavalin A-induced hepatitis.
|
30528930 |
2019 |
|
Hepatitis
|
0.100 |
Biomarker
|
group |
BEFREE |
We aimed to investigate all-cause and non-liver disease mortality according to levels of serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyltransferase (GGT) stratified by hepatitis virus infection status in a Japanese cohort.
|
30566759 |
2019 |
|
Hepatitis
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The obtained results demonstrated that diabetes initially produced liver inflammation in rats manifested by leveraging the mean levels of serum AST, ALT inducing oxidative stress resulting in a clear increase in the levels of hepatic MDA and NO concomitant with a remarkable decrease in GSH.
|
30785036 |
2019 |
|
Hepatitis
|
0.100 |
Biomarker
|
group |
BEFREE |
After oral administration of the FCCE, the increase of serum low-density lipoprotein (LDL)-cholesterol induced by HFD was suppressed significantly, as well as the level of aspartate aminotransferase, and alanine aminotransferase, which are markers of hepatitis induced by obesity.
|
30672719 |
2019 |
|
Hepatitis
|
0.100 |
Biomarker
|
group |
BEFREE |
Liver biomarkers alanine aminotransferase (ALT) and bilirubin in patients with hepatitis are above the healthy volunteer reference range (HVRR) at baseline (prior to receiving the clinical trial medication).
|
30233139 |
2018 |
|
Hepatitis
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Rifampicin-induced hepatitis was recorded where alanine aminotransferase activity (ALT) increased to both ≥5 × baseline and ≥5 × upper limit of normal (ULN), or to both ≥3 × baseline and ≥3 × ULN with concurrent elevation in serum bilirubin to ≥2 × baseline and ≥2 × ULN, in addition to a Roussel-Uclaf Causality Assessment Method score of "probable" or "highly probable" for rifampicin causality.
|
29468705 |
2018 |
|
Hepatitis
|
0.100 |
Biomarker
|
group |
BEFREE |
Alanine aminotransferase is a laboratory marker of liver function, with raised levels indicating liver dysfunction and in severe cases hepatitis.
|
29758335 |
2018 |
|
Hepatitis
|
0.100 |
Biomarker
|
group |
BEFREE |
During the first seven PICU days, the prevalence of cholestasis (> 2 mg/dL [34.2 μmol/L] bilirubin) ranged between 3.8% and 4.9% and of hypoxic hepatitis (≥ 20-fold upper limit of normality for alanine aminotransferase and aspartate aminotransferase) between 0.8% and 2.2%, both unaffected by the use of parenteral nutrition.
|
30234740 |
2018 |
|
Hepatitis
|
0.100 |
Biomarker
|
group |
BEFREE |
In the training set, the area under the receiver operating characteristic curve (AUROC) of AAGP was higher than that of ALT and aspartate transaminase (AST), to diagnose significant liver inflammation (0.77, 0.67, and 0.59, respectively, p < 0.001).
|
30337643 |
2018 |
|
Hepatitis
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Furthermore, rs1898830, rs1879026, rs187084 and rs352139 were also demonstrated to modulate the prognosis [ie, aspartate aminotransferase (AST)/alanine transaminase (ALT)>1.5] of newborns with severe hepatitis (all P<.05).
|
28703296 |
2018 |
|
Hepatitis
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Among 783 patients treated with anti-TNF (n = 472) or DMARDs only (n = 311), HBsAg-/HBcAb+ anti-TNF users had incidence of ALT elevation commensurate with uninfected counterparts (6.1 vs. 6.0/100 person-years), compared to 19.6/100 person-years in HBsAg+ patients (standardized rate ratio 3.3, 95% CI 1.3-8.2); none effected had severe or fatal hepatitis and ALT levels in all HBsAg-/HBcAb+ patients remained stable, mostly normalizing spontaneously, or after moderating treatment.
|
29694398 |
2018 |
|
Hepatitis
|
0.100 |
Biomarker
|
group |
BEFREE |
Pretreatment with emodin significantly protected mice from liver inflammation and fibrosis revealed by the decreased elevation of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST), as well as reduced hepatic necrosis and fibrosis by analysis of hematoxylin-eosin (HE) staining, Masson staining, <i>α</i>-smooth muscle actin (<i>α</i>-SMA), and collagen-I immunohistochemistry staining.
|
29743924 |
2018 |
|
Hepatitis
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Additionally, <i>caspase-1/11-/-</i> mice demonstrated significantly reduced liver inflammation with the lowest alanine aminotransferase (ALT) levels but the highest hepatic parasitic load.
|
29774028 |
2018 |
|
Hepatitis
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, we show that the level of MuRF2 expression is significantly decreased in hepatic mononuclear cells of mice with lipopolysaccharide (LPS)/d-galactosamine-induced hepatitis and negatively correlated with the serum levels of alanine aminotransferase and aspartate aminotransferase in these mice.
|
29435413 |
2018 |
|
Hepatitis
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In the training set, qAnti-HBc levels were found to have significant diagnostic value for moderate to severe liver inflammation (≥G2) in all patients (area under the receiver operating characteristic curve [AUROC] = 0.768; 95% confidence interval [CI], 0.721-0.810; P < 0.001) and in patients with normal or near-normal ALT levels (AUROC = 0.767; 95% CI, 0.697-0.828; P < 0.001).
|
28707778 |
2018 |
|
Hepatitis
|
0.100 |
Biomarker
|
group |
BEFREE |
Inexpensive and simple non-invasive indexes for predicting liver inflammation are urgently required, but have been poorly studied in chronic hepatitis B (CHB) patients with alanine transaminase (ALT) ≤2 times the upper limit of normal (ULN).
|
30542389 |
2018 |
|
Hepatitis
|
0.100 |
Biomarker
|
group |
BEFREE |
Serum markers viz, Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP) and Malondialdehyde (MDA) levels were significantly increased and the activity levels of antioxidant enzymes such as Superoxide dismutase (SOD),Catalase (CAT), Glutathione reductase (GR), Glutathione peroxidase (GPx), non-enzymatic antioxidant Glutathione (GSH) levels were decreased in the liver of hepatitis induced rats when compared to controls.
|
28152474 |
2017 |
|
Hepatitis
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim of this study was to determine whether anti-HBc could serve as a potential biomarker for the detection of liver inflammation in chronic hepatitis B (CHB) patients, especially in patients with normal ALT levels.
|
28584279 |
2017 |
|
Hepatitis
|
0.100 |
Biomarker
|
group |
BEFREE |
In children with no/minimal hepatic fibrosis and inflammatory liver disease, high ALT values are associated with LSM in the range typical of advanced fibrosis.
|
27540711 |
2017 |